Đang tải... (xem toàn văn)
Update in Heart Failure Management Definition and Stages “The inability of the heart to meet the metabolic demands of the body”Update in Heart Failure Management Definition and Stages “The inability of the heart to meet the metabolic demands of the body”Update in Heart Failure Management Definition and Stages “The inability of the heart to meet the metabolic demands of the body”
Update in Heart Failure Management New guidelines, diagnostics and treatments Casey Culbertson MD Cardiology Medical Director GE Healthcare Co-Founder MD1World MD1WORLD Lecture Series January-February, 2018 Update in Heart Failure Management Disclosures Casey Culbertson MD is a Cardiology Medical Director at GE Healthcare He owns no stock in the company and is not involved in sales of any GE products ((Adreview®) Update in Heart Failure Management Update in Heart Failure Management Definition and Stages “The inability of the heart to meet the metabolic demands of the body” Update in Heart Failure Management Update in Heart Failure Management Update in Heart Failure Management Update in Heart Failure Management Guidelines Update in Heart Failure Management Update in Heart Failure Management Treatment Algorithm Update in Heart Failure Management LCZ 696 (Entresto®) Mechanism of Action Update in Heart Failure Management New 2016 ACC/AHA/HFSA Guidelines Start Entresto instead of ACE/ARB Update in Heart Failure Management New Diagnostics for HF – PA Pressure Monitoring Update in Heart Failure Management CardioMEMS® PA Pressure Monitoring System HR PAP CO Update in Heart Failure Management “Advanced Warning” about worsening HF -> change in mortality Update in Heart Failure Management “Classic” Diagnostic Tests for Heart Failure Update in Heart Failure Management Radio-pharmaceutical agent for “prognostic” HF evaluation Low Risk H/M ratio > 1.6 High Risk H/M ratio < 1.6 Update in Heart Failure Management ADMIRE-HF Study Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study Arnold F Jacobson, MD, PHD,* Roxy Senior, MD,† Manuel D Cerqueira, MD,‡ Nathan D Wong, PHD,§ Gregory S Thomas, MD, MPH,§ Victor A Lopez, BS,§ Denis Agostini, MD, PHD, Fred Weiland, MD,ả Harish Chandna, MD,# Jagat Narula, MD, PHD,Đ on behalf of the ADMIRE-HF Investigators Objectives: The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study prospectively evaluated iodine-123 meta-iodobenzylguanidine (123I-mIBG) imaging for identifying symptomatic heart failure (HF) patients most likely to experience cardiac events Results: A total of 237 subjects (25%) experienced events (median follow-up 17 months) The hazard ratio for H/M 1.60 was 0.40 (p 0.001); the hazard ratio for continuous H/M was 0.22 (p 0.001) Two-year event rate was 15% for H/M >1.60 and 37% for H/M